Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study.
Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study.
复制标题
DOI：
10.4143/crt.2004.36.3.182
复制
发表时间：
2004-06-01
影响因子：
4.6
通讯作者：
Kwon, Sung-Joon
中科院分区：
文献类型：
--
作者：
Ahn, Myung-Ju;Oh, Ho-Suck;Kwon, Sung-Joon
目的：评价七铂、紫杉醇、5-氟尿嘧啶联合化疗治疗晚期胃癌的疗效和毒性。材料与方法：2002年7月至2003年9月，19例晚期胃癌患者接受化疗。紫杉醇135 mg/m(2)静脉滴注第1天，七铂400 mg/m(2)静脉滴注第2天，5-氟尿嘧啶800 mg/m(2)静脉滴注第2天，每3周重复一次。结果：患者年龄中位年龄60岁(范围：32~74岁)，最常见的转移部位是肝和淋巴结。在16名接受评估的患者中，总有效率为43.8%，但没有任何完全有效。疾病进展的中位时间为3.93个月(范围为0.26，约为8.1)，7个有反应的患者的中位有效时间为3.83个月(范围为1.48，约为6.07)。19例患者的中位总生存期为7.01个月(范围：0.26，约17.44)。中位数为3个周期(范围：1，约7个)，共65个周期，并对其毒性进行评估。最常见的血液学毒性是NCI I/II级贫血(47.7%)、中性粒细胞减少(9.2%)和血小板减少(6.2%)。II级以上非血液系统毒性最常见的是恶心/呕吐(30.8%/9.2%)。结论：七铂、紫杉醇和5-氟尿嘧啶联合治疗进展期胃癌具有显著的疗效和良好的毒副作用。然而，一名表现不佳的老年患者出现了危及生命的毒性/并发症。我们的结果表明，当给予表现状态良好的患者时，这种联合化疗的疗效可以最大化。还需要大量患者的进一步研究和长期的随访研究。
PURPOSE: To evaluate the efficacy and toxicity of heptaplatin, paclitaxel, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.MATERIALS AND METHODS: Between July 2002 and September 2003, nineteen patients were enrolled in this study. Paclitaxel 135 mg/m(2) iv on day 1, heptaplatin 400 mg/m(2) iv on day 2 and 5-fluorouracil 800 mg/m(2) on day 2 approximately 4 were administered and the regimen was repeated every 3 weeks.RESULTS: The median age of the patients was 60 years (range: 32 approximately 74) and the most common sites of metastasis were liver and lymph nodes. In the 16 evaluated patients, the overall response rate was 43.8%, but this was without any complete response. The median time to disease progression was 3.93 months (range: 0.26 approximately 8.1) and the median response duration for the 7 responding patients was 3.83 months (range: 1.48 approximately 6.07). The median overall survival for 19 patients was 7.01 months (range: 0.26 approximately 17.44). A median of 3 cycles (range: 1 approximately 7) and a total of 65 cycles were administered and evaluated for toxicity. The most common hematologic toxicities were NCI grade I/II anemia (47.7%), neutropenia (9.2%) and thrombocytopenia (6.2%). The most common non-hematologic toxicities more than grade II were nausea/vomiting (30.8%/9.2%). One elderly patient with ECOG 2 had a life-threatening complication of pneumonia.CONCLUSION: The combination of heptaplatin, paclitaxel, and 5-fluorouracil showed significant activity and favorable toxicity profiles in patients with advanced gastric cancer. However, one elderly patient who had poor performance experienced a life-threatening toxicity/complication. Our results suggest that the efficacy of this combination chemotherapy can be maximized when administered to the patients with good performance status. Further studies with large numbers of patients and long-term follow-up study will be needed.